Vaccination of immunocompromised subjects

Abstract

Disclosed herein are methods for enhancing immune responses to a vaccine in immunocompromised individuals, including those receiving a statin therapy. Related products are also provided.

Description

FIELD OF THE INVENTION[0001]The present disclosure generally relates to enhancing an immune response in individuals immunocompromised by medications or for other reasons.BACKGROUND OF THE INVENTION[0002]Immunosuppression induced by drugs or other reasons in a subject is an obstacle to achieving effective vaccination of the subject. It is important to note that individuals may be immunocompromised for a variety of reasons, including, for example, disease or disorder associated with immunosuppression, age (e.g., the elderly), and being on medications or medical procedures that suppress or otherwise interfere with their immune response.[0003]Certain drugs have been implicated in causing immunomodulation in patients, including statins, non-steroidal anti-inflammatory drugs (NSAIDs), interferons, and certain antipsychotic drugs, such as clozapine and haloperidol. Such immunomodulatory effects include adverse or unwanted immunosuppression in the patients, particularly those on a long-term...

AI Technical Summary

Benefits of technology

This patent describes a method for enhancing the immune response in individuals with compromised immune systems, such as those who take statin therapy. The method involves using an adjuvanted vaccine or a high-dose antigen to restore or enhance the immune response to a vaccine. This is particularly beneficial for individuals who are at risk of developing secondary infections, such as those with endocrine disorders or respiratory infections. The technical effect is improved immune protection against secondary infections in at-risk individuals.

Problems solved by technology

Immunosuppression induced by drugs or other reasons in a subject is an obstacle to achieving effective vaccination of the subject.

Such immunomodulatory effects include adverse or unwanted immunosuppression in the patients, particularly those on a long-term therapeutic regimen.

Secondary effects of a statin therapy on individuals, including both elderly and non-elderly populations, have been somewhat controversial in the literature, although most studies have concluded that statin can elicit immunomodulatory effects and that such effects are complex.

However, all NSAIDs have the potential for certain adverse effects, including potentially unwanted suppression of an immune response.

IFN therapy causes immunosuppression, in particular through neutropenia and can result in some infections manifesting in unusual ways.

In such cases, the patient co-infected with the primary pathogen (such as influenza virus) and a secondary pathogen (such as a bacterial infection) may be at elevated risk of developing complication from the secondary infection.

Some evidence shows giving interferon immediately following infection can prevent chronic hepatitis C, although diagnosis early in infection is difficult since physical symptoms are sparse in early hepatitis C infection.

IFN therapy causes immunosuppression, in particular through neutropenia and can result in some infections manifesting in unusual ways.